Skip to main content
Top
Published in: Digestive Diseases and Sciences 8/2008

01-08-2008 | Original Paper

RETRACTED ARTICLE: Gastric Changes Following Colchicine Therapy in Patients with FMF

Authors: Wael Ismail Al-Daraji, Riham M. W. Al-Mahmoud, Mohammed Ilyas

Published in: Digestive Diseases and Sciences | Issue 8/2008

Login to get access

Abstract

Background Familial Mediterranean fever (FMF) is also called recurrent polyserositis. The salient features of this disease include brief recurrent episodes of peritonitis, pleuritis, and arthritis, which are usually associated with fever. Colchicine is highly effective in the treatment of FMF and in preventing the development of recurrent attacks and amyloidosis, and it is essential to make the correct diagnosis and institute daily therapy with colchicine (0.5–0.6 mg bid). Colchicine is used to treat a variety of conditions but it is known to have gastrointestinal (GI) side effects. In this study, effects of colchicines on the gastrointestinal tract were evaluated in patients with FMF treated with colchicine. Methods Biopsies were reviewed from 43 patients attending Ain Shams University Hospital (Egypt) who were diagnosed with FMF and treated with colchicine. One-hundred and twelve GI biopsies, obtained over a 14-year period, were reviewed. This included biopsies from stomach body (38), stomach antrum (50), and colon (24). In addition, gastric biopsies were reviewed from 17 control patients who did not have FMF and were not on colchicine. Results Three patients known to have FMF and on colchicine therapy showed typical histological features of colchicine (metaphase mitoses, epithelial pseudoproliferation, mucin depletion, and frequent apoptosis). These features were seen only in gastric antral biopsies and not in colonic biopsies. None of the control group showed the characteristic morphological features of colchicine toxicity. Conclusion This is the first report of histological changes seen in the stomach following colchicine therapy. In contrast with previous reports, we did not find any definitive change in the large intestine. Our data show that gastric changes can be encountered in symptomatic patients who have recently had colchicine. If these finding are seen histologically, they merit correlation with the clinical impression and should not be interpreted as toxicity in isolation.
Literature
1.
go back to reference Cazeneuve C, Ajrapetyan H, Papin S et al (2000) Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet 67:1136–1143PubMed Cazeneuve C, Ajrapetyan H, Papin S et al (2000) Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet 67:1136–1143PubMed
2.
go back to reference Cazeneuve C, Hovannesyan Z, Genevieve D et al (2003) Familial Mediterranean fever among patients from Karabakh and the diagnostic value of MEFV gene analysis in all classically affected populations. Arthritis Rheum 48:2324–2331CrossRefPubMed Cazeneuve C, Hovannesyan Z, Genevieve D et al (2003) Familial Mediterranean fever among patients from Karabakh and the diagnostic value of MEFV gene analysis in all classically affected populations. Arthritis Rheum 48:2324–2331CrossRefPubMed
3.
go back to reference Dode C, Hazenberg BP, Pecheux C et al (2002) Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. Nephrol Dial Transplant 17:1212–1217CrossRefPubMed Dode C, Hazenberg BP, Pecheux C et al (2002) Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. Nephrol Dial Transplant 17:1212–1217CrossRefPubMed
4.
go back to reference Booth DR, Gillmore JD, Booth SE et al (1998) Pyrin/marenostrin mutations in familial Mediterranean fever. Qjm 91:603–606CrossRefPubMed Booth DR, Gillmore JD, Booth SE et al (1998) Pyrin/marenostrin mutations in familial Mediterranean fever. Qjm 91:603–606CrossRefPubMed
5.
go back to reference Booth DR, Gillmore JD, Lachmann HJ et al (2000) The genetic basis of autosomal dominant familial Mediterranean fever. Qjm 93:217–221CrossRefPubMed Booth DR, Gillmore JD, Lachmann HJ et al (2000) The genetic basis of autosomal dominant familial Mediterranean fever. Qjm 93:217–221CrossRefPubMed
6.
go back to reference Booth DR, Lachmann HJ, Gillmore JD et al (2001) Prevalence and significance of the familial Mediterranean fever gene mutation encoding pyrin Q148. Qjm 94:527–531CrossRefPubMed Booth DR, Lachmann HJ, Gillmore JD et al (2001) Prevalence and significance of the familial Mediterranean fever gene mutation encoding pyrin Q148. Qjm 94:527–531CrossRefPubMed
7.
go back to reference Chen X, Bykhovskaya Y, Tidow N et al (2000) The familial Mediterranean fever protein interacts and colocalizes with a putative Golgi transporter. Proc Soc Exp Biol Med 224:32–40CrossRefPubMed Chen X, Bykhovskaya Y, Tidow N et al (2000) The familial Mediterranean fever protein interacts and colocalizes with a putative Golgi transporter. Proc Soc Exp Biol Med 224:32–40CrossRefPubMed
8.
go back to reference Al-Alami JR, Tayeh MK, Najib DA et al (2003) Familial Mediterranean fever mutation frequencies and carrier rates among a mixed Arabic population. Saudi Med J 24:1055–1059PubMed Al-Alami JR, Tayeh MK, Najib DA et al (2003) Familial Mediterranean fever mutation frequencies and carrier rates among a mixed Arabic population. Saudi Med J 24:1055–1059PubMed
9.
go back to reference Livneh A, Aksentijevich I, Langevitz P et al (2001) A single mutated MEFV allele in Israeli patients suffering from familial Mediterranean fever and Behcet’s disease (FMF-BD). Eur J Hum Genet 9:191–196CrossRefPubMed Livneh A, Aksentijevich I, Langevitz P et al (2001) A single mutated MEFV allele in Israeli patients suffering from familial Mediterranean fever and Behcet’s disease (FMF-BD). Eur J Hum Genet 9:191–196CrossRefPubMed
10.
go back to reference Livneh A, Langevitz P, Shinar Y et al (1999) MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. Amyloid 6:1–6PubMed Livneh A, Langevitz P, Shinar Y et al (1999) MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. Amyloid 6:1–6PubMed
11.
go back to reference Settin A, El-Baz R, Abd Rasool M et al (2007) Clinical and molecular diagnosis of familial Mediterranean fever in Egyptian children. J Gastrointestin Liver Dis 16:141–145PubMed Settin A, El-Baz R, Abd Rasool M et al (2007) Clinical and molecular diagnosis of familial Mediterranean fever in Egyptian children. J Gastrointestin Liver Dis 16:141–145PubMed
12.
go back to reference Andreu JM, Timasheff SN (1982) Interaction of tubulin with single ring analogues of colchicine. Biochemistry 21:534–543CrossRefPubMed Andreu JM, Timasheff SN (1982) Interaction of tubulin with single ring analogues of colchicine. Biochemistry 21:534–543CrossRefPubMed
13.
go back to reference Anilkumar TV, Sarraf CE, Hunt T et al (1992) The nature of cytotoxic drug-induced cell death in murine intestinal crypts. Br J Cancer 65:552–558PubMed Anilkumar TV, Sarraf CE, Hunt T et al (1992) The nature of cytotoxic drug-induced cell death in murine intestinal crypts. Br J Cancer 65:552–558PubMed
14.
go back to reference Stern N, Kupferschmidt H, Meier-Abt PJ (1997) [Follow-up and therapy of acute colchicine poisoning]. Schweiz Rundsch Med Prax 86:952–956 Stern N, Kupferschmidt H, Meier-Abt PJ (1997) [Follow-up and therapy of acute colchicine poisoning]. Schweiz Rundsch Med Prax 86:952–956
15.
go back to reference Webb DI, Chodos RB, Mahar CQ et al (1968) Mechanism of vitamin B12 malabsorption in patients receiving colchicine. N Engl J Med 279:845–850PubMedCrossRef Webb DI, Chodos RB, Mahar CQ et al (1968) Mechanism of vitamin B12 malabsorption in patients receiving colchicine. N Engl J Med 279:845–850PubMedCrossRef
16.
go back to reference Ben-Chetrit E (2003) Familial Mediterranean fever (FMF) and renal AA amyloidosis-phenotype-genotype correlation, treatment and prognosis. J Nephrol 16:431–434PubMed Ben-Chetrit E (2003) Familial Mediterranean fever (FMF) and renal AA amyloidosis-phenotype-genotype correlation, treatment and prognosis. J Nephrol 16:431–434PubMed
17.
go back to reference Ben-Chetrit E, Cohen R, Chajek-Shaul T (2002) Familial Mediterranean fever and Behcet’s disease—are they associated? J Rheumatol 29:530–534PubMed Ben-Chetrit E, Cohen R, Chajek-Shaul T (2002) Familial Mediterranean fever and Behcet’s disease—are they associated? J Rheumatol 29:530–534PubMed
18.
go back to reference Ben-Chetrit E, Lerer I, Malamud E et al (2000) The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? Hum Mutat 15:385–386CrossRefPubMed Ben-Chetrit E, Lerer I, Malamud E et al (2000) The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? Hum Mutat 15:385–386CrossRefPubMed
19.
go back to reference Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum (1998)28:48–59 Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum (1998)28:48–59
20.
go back to reference Ben-Chetrit E, Levy M (2001) Enigmas in familial Mediterranean fever (FMF). Clin Exp Rheumatol 19: S1–S5PubMed Ben-Chetrit E, Levy M (2001) Enigmas in familial Mediterranean fever (FMF). Clin Exp Rheumatol 19: S1–S5PubMed
21.
go back to reference Ben-Chetrit E, Urieli-Shoval S, Calko S et al (2002) Molecular diagnosis of FMF: lessons from a study of 446 unrelated individuals. Clin Exp Rheumatol 20: S25–S29PubMed Ben-Chetrit E, Urieli-Shoval S, Calko S et al (2002) Molecular diagnosis of FMF: lessons from a study of 446 unrelated individuals. Clin Exp Rheumatol 20: S25–S29PubMed
22.
go back to reference Iacobuzio-Donahue CA, Lee EL, Abraham SC et al (2001) Colchicine toxicity: distinct morphologic findings in gastrointestinal biopsies. Am J Surg Pathol 25:1067–1073CrossRefPubMed Iacobuzio-Donahue CA, Lee EL, Abraham SC et al (2001) Colchicine toxicity: distinct morphologic findings in gastrointestinal biopsies. Am J Surg Pathol 25:1067–1073CrossRefPubMed
23.
go back to reference Parfitt JR, Driman DK (2007) Pathological effects of drugs on the gastrointestinal tract: a review. Hum Pathol 38:527–536CrossRefPubMed Parfitt JR, Driman DK (2007) Pathological effects of drugs on the gastrointestinal tract: a review. Hum Pathol 38:527–536CrossRefPubMed
24.
go back to reference Hruban RH, Yardley JH, Donehower RC et al (1989) Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. Cancer 63:1944–1950CrossRefPubMed Hruban RH, Yardley JH, Donehower RC et al (1989) Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. Cancer 63:1944–1950CrossRefPubMed
25.
go back to reference Tishler RB, Lamppu DM, Park S et al (1995) Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. Cancer Res 55:6021–6025PubMed Tishler RB, Lamppu DM, Park S et al (1995) Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. Cancer Res 55:6021–6025PubMed
26.
go back to reference Debernardis D, Sire EG, De Feudis P et al (1997) p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 57:870–874PubMed Debernardis D, Sire EG, De Feudis P et al (1997) p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 57:870–874PubMed
27.
go back to reference Woods CM, Zhu J, McQueney PA et al (1995) Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1:506–526PubMed Woods CM, Zhu J, McQueney PA et al (1995) Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1:506–526PubMed
28.
go back to reference Torres K, Horwitz SB (1998) Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 58:3620–3626PubMed Torres K, Horwitz SB (1998) Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 58:3620–3626PubMed
29.
go back to reference Haldar S, Chintapalli J, Croce CM (1996) Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56:1253–1255PubMed Haldar S, Chintapalli J, Croce CM (1996) Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56:1253–1255PubMed
30.
go back to reference Stemmermann GN, Hayashi T (1971) Colchicine intoxication. A reappraisal of its pathology based on a study of three fatal cases. Hum Pathol 2:321–332CrossRefPubMed Stemmermann GN, Hayashi T (1971) Colchicine intoxication. A reappraisal of its pathology based on a study of three fatal cases. Hum Pathol 2:321–332CrossRefPubMed
31.
go back to reference Hart J, Lewin KJ, Peters RS et al (1993) Effect of long-term colchicine therapy on jejunal mucosa. Dig Dis Sci 38:2017–2021CrossRefPubMed Hart J, Lewin KJ, Peters RS et al (1993) Effect of long-term colchicine therapy on jejunal mucosa. Dig Dis Sci 38:2017–2021CrossRefPubMed
32.
go back to reference Race TF, Paes IC, Faloon WW (1970) Intestinal malabsorption induced by oral colchicine. Comparison with neomycin and cathartic agents. Am J Med Sci 259:32–41CrossRefPubMed Race TF, Paes IC, Faloon WW (1970) Intestinal malabsorption induced by oral colchicine. Comparison with neomycin and cathartic agents. Am J Med Sci 259:32–41CrossRefPubMed
Metadata
Title
RETRACTED ARTICLE: Gastric Changes Following Colchicine Therapy in Patients with FMF
Authors
Wael Ismail Al-Daraji
Riham M. W. Al-Mahmoud
Mohammed Ilyas
Publication date
01-08-2008
Publisher
Springer-Verlag
Published in
Digestive Diseases and Sciences / Issue 8/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-0132-7

Other articles of this Issue 8/2008

Digestive Diseases and Sciences 8/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.